antibody

Anti-MYF6 Antibody

MBS8230919

0.03 mL

155 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

Antibody

Anti-MYF6 Antibody

[MYF6]

[BHLHC4; MRF4; Myogenic factor 6; Myf-6; Class C basic helix-loop-helix protein 4; bHLHc4; Muscle-specific regulatory factor 4]

[myogenic factor 6; Myogenic factor 6; myogenic factor 6; myogenic factor 6 (herculin); Class C basic helix-loop-helix protein 4; bHLHc4; Muscle-specific regulatory factor 4]

[MYF6]

[MYF6; MYF6; CNM3; MRF4; myf-6; bHLHc4; BHLHC4; MRF4; Myf-6; bHLHc4]

MYF6_HUMAN

Polyclonal

Rabbit

Human, Mouse, Rat

242

Recognizes endogenous levels of MYF6 protein.

The antibody was purified by immunogen affinity chromatography.

Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Shipping: Blue ice. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles.

Western Blot (WB)

WB (1/500 - 1/1000)

Western Blot (WB)

Immunogen: KLH-conjugated synthetic peptide encompassing a sequence within the center region of human MYF6. The exact sequence is proprietary.

Rabbit polyclonal antibody to MYF6

4505299

NP_002460.1

NM_002469.2

P23409

C-MYB Transcription Factor Network Pathway (138073); CDO In Myogenesis Pathway (1270336); Developmental Biology Pathway (1270302); Diurnally Regulated Genes With Circadian Orthologs Pathway (198813); Id Signaling Pathway (198871); Myogenesis Pathway (1270335)

The protein encoded by this gene is a probable basic helix-loop-helix (bHLH) DNA binding protein involved in muscle differentiation. The encoded protein likely acts as a heterodimer with another bHLH protein. Defects in this gene are a cause of autosomal dominant centronuclear myopathy (ADCNM). [provided by RefSeq, May 2010]

Myf-6: Involved in muscle differentiation (myogenic factor). Induces fibroblasts to differentiate into myoblasts. Probable sequence specific DNA-binding protein. Defects in MYF6 may be a cause of centronuclear myopathy type 3 (CNM3). A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers. Protein type: DNA-binding; Transcription factor. Chromosomal Location of Human Ortholog: 12q21. Cellular Component: nucleoplasm; nucleus. Molecular Function: RNA polymerase II transcription factor activity, enhancer binding; protein heterodimerization activity; transcription factor activity. Biological Process: regulation of transcription from RNA polymerase II promoter; transcription from RNA polymerase II promoter; muscle cell differentiation; skeletal muscle development; somitogenesis; positive regulation of skeletal muscle fiber development; muscle cell fate commitment; positive regulation of muscle cell differentiation; skeletal muscle regeneration; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; positive regulation of myoblast differentiation. Disease: Myopathy, Centronuclear, 3

0.03 mL

155 USD

0.1 mL

220

0.2 mL

295